Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.34 +0.73%

+$0.07 today

Market cap
$674.39M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 2.46M

Average 1.66M

KURA Total Debt

Short-term and long-term borrowings combined.

Kura Oncology, Inc.NASDAQ: KURA

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 25.4% from a year ago

Total debt stood at $24.27M at the end of Q1 FY2026, up 25.4% from a year earlier and up 18.7% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Total debt amounted to 3.7% of total assets at the end of Q1 FY2026, up 1.1 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +25.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.27M+18.7% QoQ
Last fiscal yearDec 2025
$20.46M+23.3% YoY
Year agoMar 2025
$19.35M+25.4% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.4%——
1 year+23.3%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
20.46M USD
Year-over-year change
+23.3%
4-year CAGR
+31.3%

Total Debt vs competitors

How KURA compares with its peers on the latest reported figures

  • KURA's Mar 2026 total debt of $24.27M is the 6th highest of the 11 companies compared; the peer median is $25.71M.
  • Its year-over-year change of +25.4% is the 2nd highest of 11, against a peer median of +1.3%.
  • Total debt amounts to 3.7% of total assets for KURA, versus a peer median of 3.4%.
KURA Competitors Peer median
Total Debt for KURA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$345.36M +18700.2%+568.3%73.1%
HCMHUTCHMED (China) LimitedDec 2025$97.89M +9.0%+53.6%5.6%
VSTMVerastem, Inc.Mar 2026$85.48M +11.3%+41.6%37.5%
NRIXNurix Therapeutics, Inc.Aug 2026$65.33M +15.7%+67.0%5.5%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$45.72M -25.1%+8.7%9.1%
KURAKura Oncology, Inc.Mar 2026$24.27M +25.4%+13.4%3.7%
TYRATyra Biosciences, Inc.Mar 2026$5.7M -6.9%+30.4%1.4%
ORICORIC Pharmaceuticals, Inc.Mar 2026$3.3M +2.6%-1.5%0.8%
BBOTBridgeBio Oncology Therapeutics Inc.Mar 2026$2.64M -0.2%+300.3%0.6%
CRDFCardiff Oncology, Inc.Mar 2026$646K -52.4%-32.6%1.3%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$599K +0.0%+1.9%0.4%
Peer median (excluding KURA) $25.71M+1.3%+36.0%3.4%

Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents90.67M51.8M37.32M224.46M149.1M
Short-term Investments427.29M386.18M386.64M502.93M518.14M
Net Receivables000012.6M
Inventory0000413K
Other Current Assets1.4M8.44M8.52M17.43M28.41M
Total Current Assets522.29M446.43M432.48M744.83M708.66M
Property, Plant & Equipment (Net)8.25M6.38M8.85M7.49M15.16M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets3.52M3.5M7.6M7.85M14.54M
Total Non-current Assets11.76M9.88M16.45M15.33M29.7M
Total Assets534.05M456.31M448.94M760.16M738.36M
Account Payables3.24M1.53M2.3M1.47M5.02M
Short-term Debt0002.61M0
Tax Payables0002.06M0
Deferred Revenue00024.27M48.98M
Other Current Liabilities7.92M10.3M13.15M17.51M22.37M
Total Current Liabilities22.46M24.06M35.26M78.71M116.97M
Long-term Debt09.16M9.33M6.92M9.71M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000253.91M424.91M
Other Non-current Liabilities375K265K705K1.8M3.16M
Total Non-current Liabilities4.99M11.97M16.4M267.81M447.25M
Total Liabilities27.44M36.03M51.66M346.52M564.23M
Common Stock7K7K7K8K9K
Retained Earnings(432.97M)(568.81M)(721.44M)(895.42M)(1.17B)
Accumulated OCI(1.79M)(8.03M)(1.27M)764K1.02M
Other Stockholders Equity00000
Minority Interest00000
Total Equity506.61M420.28M397.27M413.64M174.14M
Total Debt6.88M14.02M17.2M16.59M20.46M
Net Debt(83.8M)(37.78M)(20.12M)(207.87M)(128.64M)

Kura Oncology, Inc.

NASDAQ:KURA

Intrinsic Alpha fair value

Locked

Current Price

$7.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.